Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies
Authors:
Open Access
- 15 September 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 67 (11) , 1528-1536
Abstract
Objectives: Previously reported HPLC methods for gemcitabine determination are time-consuming with complicated mobile phases and gradient elution. Thus, a sensitive and stability-indicating isocratic HPLC method, which provides simple, fast and precise measurements, was developed. This method was applied to study the digestive enzymatic degradation of gemcitabine, for the first time, and the protection afforded following incorporation into poly lactic-co-glycolic acid (PLGA) nanoparticles. Methods: An analytical HPLC method was developed with an optimized combination of operating conditions. Forced degradation and application of the method to in-vitro drug release studies were conducted. Finally, gemcitabine-loaded nanoparticles were exposed to the digestive enzymes pepsin, trypsin and α-chymotrypsin, and the resulting degradation evaluated. Key findings: The analytical method was linear between 1 and 100 μg/ml, with excellent accuracy of 99.91–101.77% and precision of 1.71 or lower, with a 0.014 μg/ml limit of detection (LOD) and a 0.043 μg/ml limit of quantification (LOQ). Following exposure of gemcitabine to stressors, the drug was relatively stable in strong acid (1 N HCl), base (1 N NaOH) and as an aqueous solution exposed to light over 7 days, with less than 10% degradation. However, gemcitabine was more susceptible to degradation at 70°C and oxidative conditions (3% v/v H2O2) with greater than 10% degradation noted after 7 days. In-vitro drug release studies demonstrated a sustained drug release profile from PLGA nanoparticles, which also improved the resistance of gemcitabine to enzymatic degradation. Conclusion: These results demonstrate the utility and effectiveness of this simple isocratic HPLC method in evaluating the overall performance of a gemcitabine-loaded formulation.Keywords
Funding Information
- School of Pharmacy, Faculty of Medical and Health Science, University of Auckland
This publication has 22 references indexed in Scilit:
- The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpressionBiomaterials, 2013
- Development of an isocratic HPLC method for catechin quantification and its application to formulation studiesFitoterapia, 2012
- Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticlesInternational Journal of Pharmaceutics, 2012
- Microemulsions for Intravesical Delivery of GemcitabineChemical and Pharmaceutical Bulletin, 2010
- Liposomal gemcitabine (GemLip)—efficient drug against hormone‐refractory Du145 and PC‐3 prostate cancer xenograftsThe Prostate, 2009
- Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic StudyClinical Cancer Research, 2008
- Understanding Ribonucleotide Reductase Inactivation by GemcitabineChemistry – A European Journal, 2007
- Rapid determination of gemcitabine in plasma and serum using reversed‐phase HPLCJournal of Separation Science, 2007
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug ResistanceChemical Reviews, 2003